|2nd October 2020||Mara G. Aspinall||2,500||Open or private sale||$52.48||$131,200.00|
|25th September 2020||James A Datin||1,492||Grant/award etc.||$10.89||$16,247.88|
|25th September 2020||James A Datin||408||Payment by withholding||$10.89||$4,443.12|
|9th September 2020||Mara G. Aspinall||2,500||Open or private sale||$50.48||$126,200.00|
|4th September 2020||Mara G. Aspinall||2,500||Open or private sale||$48.48||$121,200.00|
|28th August 2020||Mara G. Aspinall||2,500||Open or private sale||$46.48||$116,200.00|
|23rd June 2020||James A Datin||455||Payment by withholding||$9.74||$4,433.75|
|23rd June 2020||James A Datin||1,667||Grant/award etc.||$9.74||$16,244.08|
|1st June 2020||Lelio Marmora||7,015||Grant/award etc.||$14.26||$99,998.83|
|21st May 2020||Mara G. Aspinall||30,582||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic and collection devices and other technologies. It operates through the OSUR and DNAG segments. The OSUR segment develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices. The DNAG segment manufactures and sells specimen collection kits that are used for molecular testing.